Skip to main content
. 2018 Aug 3;109(9):2881–2888. doi: 10.1111/cas.13736

Table 2.

Health state probabilities used in the model, based on the Japanese phase II trial of aprepitant15

Health state outcomes by phase Aprepitant regimen (n = 146) Nonaprepitant regimen (n = 149)
Acute phase (day 1) Delayed phase (days 2‐5)
% %
CP CP 61.6 43.0
CRB 5.5 6.0
IR 16.4 32.9
CRB CP 2.1 1.3
CRB 1.4 0
IR 0 0
IR CP 1.4 0
CRB 0 1.3
IR 11.0 15.4

CP, complete protection; CRB, complete response at best; IR, incomplete response.